HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Carmelo Carlo-Stella, Stephen Ansell, Pier Luigi Zinzani, John Radford, Kami Maddocks, Antonio Pinto, Graham P. Collins, Veronika Bachanova, Nancy Bartlett, Isabelle Bence-Bruckler, Mehdi Hamadani, Justin Kline, Jiri Mayer, Kerry J. Savage, Ranjana Advani, Paolo Calmi, René Olivier Casasnovas, Tatyana Feldman, Brian Hess, Mariana Bastos-OreiroSunil Iyengar, Sandy Eisen, Yanina Negievich, Luqiang Wang, Jens Wuerthner, Alex F. Herrera

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)'. Together they form a unique fingerprint.

Medicine & Life Sciences